Infertility Treatment Market

Infertility Treatment Market by Procedure (Assisted Reproductive Technology (ART), Artificial Insemination, Fertility Surgeries,), by Product (Instruments, Media & Consumables, Accessories), by Patient Type (Male treatment, Female Treatment), by End User (Fertility Centers, Hospitals and Clinics, Research Institutes, Cryobanks) – Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023

Delivery : 24-72 Working Hours
Report Code: LS11134
Available Format:

Infertility Treatment Market Overview

Infertility is a condition where, a person is unable to reproduce by natural means. Treatment of the infertility depends on the cause of the condition. The various causes of infertility include sexually transmitted infections, genetic problems, DNA damage due to smoking, diabetes mellitus, and toxins such as chemical dusts, glues and pesticides. According to the Center for Disease Control and Prevention (CDC), there are around 6.9 million women aged 15-44 years, who have ever used infertility services. The global infertility treatment market is increasing significantly due to the changing lifestyle and exposure to harmful chemicals via pollution.

On the basis of procedure, the infertility treatment market is segmented into assisted reproductive technology (ART), artificial insemination, fertility surgeries, and other procedures such as egg freezing, sperm freezing, and embryo freezing. Assisted reproductive technology (ART) held the largest share of the market in 2016, due to the technological advancements and high prevalence of lifestyle disorders which is further leading to a decline in the fertility rate.

Based on the product, the infertility market is segmented into instruments, media & consumables, and accessories. Instruments accounted for the largest share in the infertility market in 2016, due to its application in wide range of treatment processes such as surgery, intrauterine insemination, in vitro fertilization, and intracytoplasmic sperm injection.

On the basis of the type of the patient, the infertility market is segmented into male treatment and female treatment. The female treatment segment accounted for the larger share in the infertility treatment market in 2016, due to the decrease in the fertility of the females and availability of broad range of treatment processes.

Infertility Treatment Market Dynamics

Growth Drivers

infertility treatment market is expected to grow significantly during the forecast period (2017-2023). The major factors driving growth of the infertility treatment market are continuous decline in fertility rates, high prevalence of lifestyle disorders, growing public awareness about infertility and the available treatment options, and technological advancements in infertility treatment devices.

Smoking is one of the major reasons for the decline in fertility rates and high prevalence of lifestyle disorders. According to the Center for Disease Control & Prevention (CDC), smoking kills more than 480,000 people every year in the U.S. Smoking reduces fertility in female ovocytes and in male sperm. As per the reports of World Health Organization (WHO), every year tobacco kills more than 7 million people worldwide. Thus, the various disorders caused by the smoking and decline in the fertility rate are driving the growth of the infertility treatment market.


The risk and complications associated with the infertility treatment, high procedural cost of assisted reproductive techniques in developed markets and unsupportive government regulations for certain infertility treatment options act as major barriers for the growth of the infertility treatment market.


The improving healthcare infrastructure in emerging economies, increasing medical tourism due to low treatment costs, and use of fertility treatment options by single parents and same-sex couples are creating ample opportunities for the growth of the infertility treatment market.

Healthcare industry is undergoing rapid changes in the emerging economies due to rising government expenditure, increasing number of hospitals, increase in the number of surgeries, and rising healthcare awareness. Emerging economies provide a suitable opportunity for the growth of the infertility treatment market. In emerging economies such as India, China, Brazil, and Mexico, government is increasingly spending on the healthcare. According to World Bank, Brazil spent 8.3% of $2.456 trillion GDP on healthcare in 2014. Similarly, China spent 5.5% of its GDP on healthcare, whereas, Mexico spent 6.3% of GDP on healthcare, in 2014.

Infertility Treatment Market Insights by Geography

Geographically, North America was the largest market for infertility treatment in 2016, followed by Europe. The North American infertility treatment market is primarily driven by increase in the number of same-sex couples, technological advancements, declining fertility rates, and high healthcare expenditure in the region.

Asia-Pacific is expected to witness the fastest growth in the forecasted period (2017-2023), due to the increasing medical tourism, growing healthcare expenditure, increasing population, and reduction in treatment prices.

Infertility Treatment Market Competitive Landscape

Some of the key players in the infertility treatment market include Cooper Companies Inc., Cook Group Incorporated, Vitrolife AB, Genea Limited, Irvine Scientific, The Baker Company, Inc., IVFtech ApS, Esco Micro Pte. Ltd., Thermo Fisher Scientific, Inc., and Labotect GmbH.

The key players are expanding their presence in the market by making strategic acquisition. In November 2016, Cooper Companies, Inc. announced that CooperSurgical had acquired Wallace, the in-vitro fertilization (IVF) segment of Smiths Medical, a division of Smiths Group plc. The purchase price was approximately $168 million subject to customary closing adjustments. The acquisition was a strategic fit with the existing IVF portfolio as Wallace was expected to bring the gold standard of embryo transfer catheters along with several other premier products such as oocyte retrieval needles.

In May 2016, Cooper Companies, Inc. CooperSurgical had acquired the commercial assets of Recombine Inc., a clinical genetic testing company specializing in carrier screening. The acquisition was an exceptional fit for CooperSurgical as it adds the premier carrier screening test sold within the IVF marketplace to the existing IVF genetic testing platform.


By Procedure

  • Assisted Reproductive Technology (ART)
  • In-vitro Fertilization (IVF)
  • Intracytoplasmic Sperm Injection (ICSI)
  • Gamete Donation
  • Surrogacy
  • Artificial Insemination
  • Intrauterine Insemination
  • Intracervical Insemination
  • Intratubal Insemination
  • Fertility Surgeries
  • Others

By Products

  • Instruments
  • Micromanipulator Systems
  • Laser Systems
  • Imaging Systems
  • Ovum Aspiration Pumps
  • Sperm Analyzers
  • Incubators
  • Gas Analyzers
  • Workstations
  • Media & Consumables
  • Accessories

By Patient type

  • Male Treatment
  • Female Treatment

By End User

  • Fertility Centers
  • Hospitals and Clinics
  • Research Institutes
  • Cryobanks

Geographical Segmentation

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • UAE
    • South Africa

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry